Improved survival after LTx‐associated acute GVHD with mAb therapy targeting IL2RAb and soluble TNFAb: Single‐center experience and systematic review
Acute graft‐versus‐host disease (GVHD) after liver transplant (LTx) is a rare complication with a high mortality rate. Recently, monoclonal antibody (mAb) treatment, specifically with anti–interleukin 2 receptor antibodies (IL2RAb) and anti–tumor necrosis factor‐α antibodies (TNFAb), has gained incr...
Gespeichert in:
| Veröffentlicht in: | American journal of transplantation 2018-12, Vol.18 (12), p.3007-3020 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 3020 |
|---|---|
| container_issue | 12 |
| container_start_page | 3007 |
| container_title | American journal of transplantation |
| container_volume | 18 |
| creator | Minnee, R. C. Fieuws, S. Jochmans, I. Aerts, R. Sainz Barriga, M. Debaveye, Y. Maertens, J. Vandenberghe, P. Laleman, W. Merwe, S. Verslype, C. Cassiman, D. Ferdinande, P. Nevens, F. Pirenne, J. Monbaliu, D. |
| description | Acute graft‐versus‐host disease (GVHD) after liver transplant (LTx) is a rare complication with a high mortality rate. Recently, monoclonal antibody (mAb) treatment, specifically with anti–interleukin 2 receptor antibodies (IL2RAb) and anti–tumor necrosis factor‐α antibodies (TNFAb), has gained increasing interest. However, evidence is mostly limited to case reports and the efficacy remains unclear. Here, we describe 5 patients with LTx‐associated GVHD from our center and provide the results of our systematic literature review to evaluate the potential therapeutic benefit of IL2RAb/TNFAb treatment. Of the combined population of 155 patients (5 in our center and 150 through systematic search), 24 were given mAb (15.5%)—4 with TNFAb (2.6%) and 17 with IL2RAb (11%) (“mAb group”)—and compared with patients who received other treatments (referred to as “no‐mAb group”). Two‐sided Fisher exact tests revealed a better survival when comparing treatment with mAb versus no‐mAb (11/24 vs 27/131; P = .018), TNFAb versus no‐mAb (3/4 vs 27/131; P = .034), and IL2RAb versus no‐mAb (8/17 vs 27/131; P = .029). This systematic review suggests a beneficial effect of mAb treatment and a promising role for TNFAb and IL2RAb as a first‐line strategy to treat LTx‐associated acute GVHD.
This cases series and systematic review reveals a beneficial effect of monoclonal antibody treatment and a promising role for anti‐TNF‐α antibody and anti‐interleukin‐2 receptor antibody to treat liver transplantation–associated acute graft‐versus‐host disease as a first‐line strategy. |
| doi_str_mv | 10.1111/ajt.14923 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2036203038</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2036203038</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3883-2f13bd877aff751091bd3198fc5a779755b8b0ee24520ff206ef72368f0428653</originalsourceid><addsrcrecordid>eNp1kctuEzEUhi0EohdY8ALIEhu6SOvLeOxhFxXapoqKBIGt5XGOW0dzCbYnaXY8AltejyfB7ZQukGrJsqX_03cs_wi9oeSY5nViVumYFhXjz9A-LQmZlLTgzx_vXOyhgxhXhFDJFHuJ9lgleSEI30e_Z-069BtY4jiEjd-YBhuXIOD54vbPz18mxt56k3Ju7JAAn3-_-Ii3Pt3gdlrjdAPBrHc4mXANyXfXeDZnX3Jguizsm6FuAC-uzqb1B_w1xw1kp4XubgDcriF46CyM9C4maE3yFgfYeNi-Qi-caSK8fjgP0bezT4vTi8n88_nsdDqfWK4UnzBHeb1UUhrnpKCkovWS00o5K4yUlRSiVjUBYIVgxDlGSnCS8VI5UjBVCn6I3o_e_A8_BohJtz5aaBrTQT9EzQgv8yZcZfTdf-iqH0KXX6cZ5Xm6ULzI1NFI2dDHGMDpdfCtCTtNib7rS-e-9H1fmX37YBzqFpaP5L-CMnAyAlvfwO5pk55eLkblX0gvoMo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2137515834</pqid></control><display><type>article</type><title>Improved survival after LTx‐associated acute GVHD with mAb therapy targeting IL2RAb and soluble TNFAb: Single‐center experience and systematic review</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Minnee, R. C. ; Fieuws, S. ; Jochmans, I. ; Aerts, R. ; Sainz Barriga, M. ; Debaveye, Y. ; Maertens, J. ; Vandenberghe, P. ; Laleman, W. ; Merwe, S. ; Verslype, C. ; Cassiman, D. ; Ferdinande, P. ; Nevens, F. ; Pirenne, J. ; Monbaliu, D.</creator><creatorcontrib>Minnee, R. C. ; Fieuws, S. ; Jochmans, I. ; Aerts, R. ; Sainz Barriga, M. ; Debaveye, Y. ; Maertens, J. ; Vandenberghe, P. ; Laleman, W. ; Merwe, S. ; Verslype, C. ; Cassiman, D. ; Ferdinande, P. ; Nevens, F. ; Pirenne, J. ; Monbaliu, D.</creatorcontrib><description>Acute graft‐versus‐host disease (GVHD) after liver transplant (LTx) is a rare complication with a high mortality rate. Recently, monoclonal antibody (mAb) treatment, specifically with anti–interleukin 2 receptor antibodies (IL2RAb) and anti–tumor necrosis factor‐α antibodies (TNFAb), has gained increasing interest. However, evidence is mostly limited to case reports and the efficacy remains unclear. Here, we describe 5 patients with LTx‐associated GVHD from our center and provide the results of our systematic literature review to evaluate the potential therapeutic benefit of IL2RAb/TNFAb treatment. Of the combined population of 155 patients (5 in our center and 150 through systematic search), 24 were given mAb (15.5%)—4 with TNFAb (2.6%) and 17 with IL2RAb (11%) (“mAb group”)—and compared with patients who received other treatments (referred to as “no‐mAb group”). Two‐sided Fisher exact tests revealed a better survival when comparing treatment with mAb versus no‐mAb (11/24 vs 27/131; P = .018), TNFAb versus no‐mAb (3/4 vs 27/131; P = .034), and IL2RAb versus no‐mAb (8/17 vs 27/131; P = .029). This systematic review suggests a beneficial effect of mAb treatment and a promising role for TNFAb and IL2RAb as a first‐line strategy to treat LTx‐associated acute GVHD.
This cases series and systematic review reveals a beneficial effect of monoclonal antibody treatment and a promising role for anti‐TNF‐α antibody and anti‐interleukin‐2 receptor antibody to treat liver transplantation–associated acute graft‐versus‐host disease as a first‐line strategy.</description><identifier>ISSN: 1600-6135</identifier><identifier>EISSN: 1600-6143</identifier><identifier>DOI: 10.1111/ajt.14923</identifier><identifier>PMID: 29734503</identifier><language>eng</language><publisher>United States: Elsevier Limited</publisher><subject>Adult ; Aged ; Antibodies, Monoclonal - therapeutic use ; Case reports ; Clinical outcomes ; clinical research/practice ; complication ; Evidence-based medicine ; Female ; Follow-Up Studies ; Graft Rejection - drug therapy ; Graft Rejection - etiology ; Graft Rejection - mortality ; Graft Survival ; Graft vs Host Disease - drug therapy ; Graft vs Host Disease - etiology ; Graft vs Host Disease - mortality ; Graft-versus-host reaction ; graft‐versus‐host disease (GVHD) ; Humans ; Immunotherapy ; Interleukin 2 ; Interleukin-2 Receptor alpha Subunit - antagonists & inhibitors ; Literature reviews ; Liver diseases ; Liver transplantation ; Liver Transplantation - adverse effects ; Liver Transplantation - mortality ; liver transplantation/hepatology ; Liver transplants ; Male ; Middle Aged ; Monoclonal antibodies ; Patients ; Postoperative Complications ; Prognosis ; Retrospective Studies ; Risk Factors ; Survival ; Survival Rate ; Systematic review ; Transplants & implants ; Tumor Necrosis Factor-alpha - antagonists & inhibitors</subject><ispartof>American journal of transplantation, 2018-12, Vol.18 (12), p.3007-3020</ispartof><rights>2018 The American Society of Transplantation and the American Society of Transplant Surgeons</rights><rights>2018 The American Society of Transplantation and the American Society of Transplant Surgeons.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3883-2f13bd877aff751091bd3198fc5a779755b8b0ee24520ff206ef72368f0428653</citedby><cites>FETCH-LOGICAL-c3883-2f13bd877aff751091bd3198fc5a779755b8b0ee24520ff206ef72368f0428653</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fajt.14923$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fajt.14923$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29734503$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Minnee, R. C.</creatorcontrib><creatorcontrib>Fieuws, S.</creatorcontrib><creatorcontrib>Jochmans, I.</creatorcontrib><creatorcontrib>Aerts, R.</creatorcontrib><creatorcontrib>Sainz Barriga, M.</creatorcontrib><creatorcontrib>Debaveye, Y.</creatorcontrib><creatorcontrib>Maertens, J.</creatorcontrib><creatorcontrib>Vandenberghe, P.</creatorcontrib><creatorcontrib>Laleman, W.</creatorcontrib><creatorcontrib>Merwe, S.</creatorcontrib><creatorcontrib>Verslype, C.</creatorcontrib><creatorcontrib>Cassiman, D.</creatorcontrib><creatorcontrib>Ferdinande, P.</creatorcontrib><creatorcontrib>Nevens, F.</creatorcontrib><creatorcontrib>Pirenne, J.</creatorcontrib><creatorcontrib>Monbaliu, D.</creatorcontrib><title>Improved survival after LTx‐associated acute GVHD with mAb therapy targeting IL2RAb and soluble TNFAb: Single‐center experience and systematic review</title><title>American journal of transplantation</title><addtitle>Am J Transplant</addtitle><description>Acute graft‐versus‐host disease (GVHD) after liver transplant (LTx) is a rare complication with a high mortality rate. Recently, monoclonal antibody (mAb) treatment, specifically with anti–interleukin 2 receptor antibodies (IL2RAb) and anti–tumor necrosis factor‐α antibodies (TNFAb), has gained increasing interest. However, evidence is mostly limited to case reports and the efficacy remains unclear. Here, we describe 5 patients with LTx‐associated GVHD from our center and provide the results of our systematic literature review to evaluate the potential therapeutic benefit of IL2RAb/TNFAb treatment. Of the combined population of 155 patients (5 in our center and 150 through systematic search), 24 were given mAb (15.5%)—4 with TNFAb (2.6%) and 17 with IL2RAb (11%) (“mAb group”)—and compared with patients who received other treatments (referred to as “no‐mAb group”). Two‐sided Fisher exact tests revealed a better survival when comparing treatment with mAb versus no‐mAb (11/24 vs 27/131; P = .018), TNFAb versus no‐mAb (3/4 vs 27/131; P = .034), and IL2RAb versus no‐mAb (8/17 vs 27/131; P = .029). This systematic review suggests a beneficial effect of mAb treatment and a promising role for TNFAb and IL2RAb as a first‐line strategy to treat LTx‐associated acute GVHD.
This cases series and systematic review reveals a beneficial effect of monoclonal antibody treatment and a promising role for anti‐TNF‐α antibody and anti‐interleukin‐2 receptor antibody to treat liver transplantation–associated acute graft‐versus‐host disease as a first‐line strategy.</description><subject>Adult</subject><subject>Aged</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Case reports</subject><subject>Clinical outcomes</subject><subject>clinical research/practice</subject><subject>complication</subject><subject>Evidence-based medicine</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Graft Rejection - drug therapy</subject><subject>Graft Rejection - etiology</subject><subject>Graft Rejection - mortality</subject><subject>Graft Survival</subject><subject>Graft vs Host Disease - drug therapy</subject><subject>Graft vs Host Disease - etiology</subject><subject>Graft vs Host Disease - mortality</subject><subject>Graft-versus-host reaction</subject><subject>graft‐versus‐host disease (GVHD)</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>Interleukin 2</subject><subject>Interleukin-2 Receptor alpha Subunit - antagonists & inhibitors</subject><subject>Literature reviews</subject><subject>Liver diseases</subject><subject>Liver transplantation</subject><subject>Liver Transplantation - adverse effects</subject><subject>Liver Transplantation - mortality</subject><subject>liver transplantation/hepatology</subject><subject>Liver transplants</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Monoclonal antibodies</subject><subject>Patients</subject><subject>Postoperative Complications</subject><subject>Prognosis</subject><subject>Retrospective Studies</subject><subject>Risk Factors</subject><subject>Survival</subject><subject>Survival Rate</subject><subject>Systematic review</subject><subject>Transplants & implants</subject><subject>Tumor Necrosis Factor-alpha - antagonists & inhibitors</subject><issn>1600-6135</issn><issn>1600-6143</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kctuEzEUhi0EohdY8ALIEhu6SOvLeOxhFxXapoqKBIGt5XGOW0dzCbYnaXY8AltejyfB7ZQukGrJsqX_03cs_wi9oeSY5nViVumYFhXjz9A-LQmZlLTgzx_vXOyhgxhXhFDJFHuJ9lgleSEI30e_Z-069BtY4jiEjd-YBhuXIOD54vbPz18mxt56k3Ju7JAAn3-_-Ii3Pt3gdlrjdAPBrHc4mXANyXfXeDZnX3Jguizsm6FuAC-uzqb1B_w1xw1kp4XubgDcriF46CyM9C4maE3yFgfYeNi-Qi-caSK8fjgP0bezT4vTi8n88_nsdDqfWK4UnzBHeb1UUhrnpKCkovWS00o5K4yUlRSiVjUBYIVgxDlGSnCS8VI5UjBVCn6I3o_e_A8_BohJtz5aaBrTQT9EzQgv8yZcZfTdf-iqH0KXX6cZ5Xm6ULzI1NFI2dDHGMDpdfCtCTtNib7rS-e-9H1fmX37YBzqFpaP5L-CMnAyAlvfwO5pk55eLkblX0gvoMo</recordid><startdate>201812</startdate><enddate>201812</enddate><creator>Minnee, R. C.</creator><creator>Fieuws, S.</creator><creator>Jochmans, I.</creator><creator>Aerts, R.</creator><creator>Sainz Barriga, M.</creator><creator>Debaveye, Y.</creator><creator>Maertens, J.</creator><creator>Vandenberghe, P.</creator><creator>Laleman, W.</creator><creator>Merwe, S.</creator><creator>Verslype, C.</creator><creator>Cassiman, D.</creator><creator>Ferdinande, P.</creator><creator>Nevens, F.</creator><creator>Pirenne, J.</creator><creator>Monbaliu, D.</creator><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7T5</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>201812</creationdate><title>Improved survival after LTx‐associated acute GVHD with mAb therapy targeting IL2RAb and soluble TNFAb: Single‐center experience and systematic review</title><author>Minnee, R. C. ; Fieuws, S. ; Jochmans, I. ; Aerts, R. ; Sainz Barriga, M. ; Debaveye, Y. ; Maertens, J. ; Vandenberghe, P. ; Laleman, W. ; Merwe, S. ; Verslype, C. ; Cassiman, D. ; Ferdinande, P. ; Nevens, F. ; Pirenne, J. ; Monbaliu, D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3883-2f13bd877aff751091bd3198fc5a779755b8b0ee24520ff206ef72368f0428653</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Case reports</topic><topic>Clinical outcomes</topic><topic>clinical research/practice</topic><topic>complication</topic><topic>Evidence-based medicine</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Graft Rejection - drug therapy</topic><topic>Graft Rejection - etiology</topic><topic>Graft Rejection - mortality</topic><topic>Graft Survival</topic><topic>Graft vs Host Disease - drug therapy</topic><topic>Graft vs Host Disease - etiology</topic><topic>Graft vs Host Disease - mortality</topic><topic>Graft-versus-host reaction</topic><topic>graft‐versus‐host disease (GVHD)</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>Interleukin 2</topic><topic>Interleukin-2 Receptor alpha Subunit - antagonists & inhibitors</topic><topic>Literature reviews</topic><topic>Liver diseases</topic><topic>Liver transplantation</topic><topic>Liver Transplantation - adverse effects</topic><topic>Liver Transplantation - mortality</topic><topic>liver transplantation/hepatology</topic><topic>Liver transplants</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Monoclonal antibodies</topic><topic>Patients</topic><topic>Postoperative Complications</topic><topic>Prognosis</topic><topic>Retrospective Studies</topic><topic>Risk Factors</topic><topic>Survival</topic><topic>Survival Rate</topic><topic>Systematic review</topic><topic>Transplants & implants</topic><topic>Tumor Necrosis Factor-alpha - antagonists & inhibitors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Minnee, R. C.</creatorcontrib><creatorcontrib>Fieuws, S.</creatorcontrib><creatorcontrib>Jochmans, I.</creatorcontrib><creatorcontrib>Aerts, R.</creatorcontrib><creatorcontrib>Sainz Barriga, M.</creatorcontrib><creatorcontrib>Debaveye, Y.</creatorcontrib><creatorcontrib>Maertens, J.</creatorcontrib><creatorcontrib>Vandenberghe, P.</creatorcontrib><creatorcontrib>Laleman, W.</creatorcontrib><creatorcontrib>Merwe, S.</creatorcontrib><creatorcontrib>Verslype, C.</creatorcontrib><creatorcontrib>Cassiman, D.</creatorcontrib><creatorcontrib>Ferdinande, P.</creatorcontrib><creatorcontrib>Nevens, F.</creatorcontrib><creatorcontrib>Pirenne, J.</creatorcontrib><creatorcontrib>Monbaliu, D.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>American journal of transplantation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Minnee, R. C.</au><au>Fieuws, S.</au><au>Jochmans, I.</au><au>Aerts, R.</au><au>Sainz Barriga, M.</au><au>Debaveye, Y.</au><au>Maertens, J.</au><au>Vandenberghe, P.</au><au>Laleman, W.</au><au>Merwe, S.</au><au>Verslype, C.</au><au>Cassiman, D.</au><au>Ferdinande, P.</au><au>Nevens, F.</au><au>Pirenne, J.</au><au>Monbaliu, D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Improved survival after LTx‐associated acute GVHD with mAb therapy targeting IL2RAb and soluble TNFAb: Single‐center experience and systematic review</atitle><jtitle>American journal of transplantation</jtitle><addtitle>Am J Transplant</addtitle><date>2018-12</date><risdate>2018</risdate><volume>18</volume><issue>12</issue><spage>3007</spage><epage>3020</epage><pages>3007-3020</pages><issn>1600-6135</issn><eissn>1600-6143</eissn><abstract>Acute graft‐versus‐host disease (GVHD) after liver transplant (LTx) is a rare complication with a high mortality rate. Recently, monoclonal antibody (mAb) treatment, specifically with anti–interleukin 2 receptor antibodies (IL2RAb) and anti–tumor necrosis factor‐α antibodies (TNFAb), has gained increasing interest. However, evidence is mostly limited to case reports and the efficacy remains unclear. Here, we describe 5 patients with LTx‐associated GVHD from our center and provide the results of our systematic literature review to evaluate the potential therapeutic benefit of IL2RAb/TNFAb treatment. Of the combined population of 155 patients (5 in our center and 150 through systematic search), 24 were given mAb (15.5%)—4 with TNFAb (2.6%) and 17 with IL2RAb (11%) (“mAb group”)—and compared with patients who received other treatments (referred to as “no‐mAb group”). Two‐sided Fisher exact tests revealed a better survival when comparing treatment with mAb versus no‐mAb (11/24 vs 27/131; P = .018), TNFAb versus no‐mAb (3/4 vs 27/131; P = .034), and IL2RAb versus no‐mAb (8/17 vs 27/131; P = .029). This systematic review suggests a beneficial effect of mAb treatment and a promising role for TNFAb and IL2RAb as a first‐line strategy to treat LTx‐associated acute GVHD.
This cases series and systematic review reveals a beneficial effect of monoclonal antibody treatment and a promising role for anti‐TNF‐α antibody and anti‐interleukin‐2 receptor antibody to treat liver transplantation–associated acute graft‐versus‐host disease as a first‐line strategy.</abstract><cop>United States</cop><pub>Elsevier Limited</pub><pmid>29734503</pmid><doi>10.1111/ajt.14923</doi><tpages>14</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1600-6135 |
| ispartof | American journal of transplantation, 2018-12, Vol.18 (12), p.3007-3020 |
| issn | 1600-6135 1600-6143 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2036203038 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Adult Aged Antibodies, Monoclonal - therapeutic use Case reports Clinical outcomes clinical research/practice complication Evidence-based medicine Female Follow-Up Studies Graft Rejection - drug therapy Graft Rejection - etiology Graft Rejection - mortality Graft Survival Graft vs Host Disease - drug therapy Graft vs Host Disease - etiology Graft vs Host Disease - mortality Graft-versus-host reaction graft‐versus‐host disease (GVHD) Humans Immunotherapy Interleukin 2 Interleukin-2 Receptor alpha Subunit - antagonists & inhibitors Literature reviews Liver diseases Liver transplantation Liver Transplantation - adverse effects Liver Transplantation - mortality liver transplantation/hepatology Liver transplants Male Middle Aged Monoclonal antibodies Patients Postoperative Complications Prognosis Retrospective Studies Risk Factors Survival Survival Rate Systematic review Transplants & implants Tumor Necrosis Factor-alpha - antagonists & inhibitors |
| title | Improved survival after LTx‐associated acute GVHD with mAb therapy targeting IL2RAb and soluble TNFAb: Single‐center experience and systematic review |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T17%3A30%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Improved%20survival%20after%20LTx%E2%80%90associated%20acute%20GVHD%20with%20mAb%20therapy%20targeting%20IL2RAb%20and%20soluble%20TNFAb:%20Single%E2%80%90center%20experience%20and%20systematic%20review&rft.jtitle=American%20journal%20of%20transplantation&rft.au=Minnee,%20R.%20C.&rft.date=2018-12&rft.volume=18&rft.issue=12&rft.spage=3007&rft.epage=3020&rft.pages=3007-3020&rft.issn=1600-6135&rft.eissn=1600-6143&rft_id=info:doi/10.1111/ajt.14923&rft_dat=%3Cproquest_cross%3E2036203038%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2137515834&rft_id=info:pmid/29734503&rfr_iscdi=true |